Recruiting

Testing a new medication for recurrent brain tumors with specific genetic mutations

Plain-English translation of NCT05588141 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new medication called to treat recurrent malignant gliomas — aggressive brain tumors that have come back after previous treatment. The study focuses on patients whose tumors have specific genetic mutations (IDH1 or IDH2). Early research suggests this medication may work especially well against brain tumors with these mutations.

Recurrent brain tumors are difficult to treat and patients often have limited options after their cancer comes back. This medication has shown promise in early studies, particularly for tumors with these genetic mutations, so researchers want to find the right dose and test whether it actually helps patients live longer without their cancer getting worse.

Do you qualify?

You likely qualify if…

you are at least 15 years old
you have been diagnosed with a recurrent malignant glioma (brain tumor that has returned) with an IDH1 or IDH2 genetic mutation confirmed by testing
you have received prior treatment such as radiation therapy or chemotherapy before your cancer came back
you are in good enough overall health to tolerate treatment (Karnofsky performance status of 70% or higher)
your blood work and organ function meet certain safety standards

You likely don't qualify if…

you have had the cancer drug bevacizumab as a previous brain tumor treatment
you have had too many recurrences of your tumor (more than one relapse for grade 3–4 tumors, or more than two relapses for grade 2 tumors in Phase II)
you have received certain chemotherapy drugs within a specific timeframe before starting the study
you have had surgery or radiation therapy very recently (within 14–42 days depending on the treatment)
you are pregnant, breastfeeding, or unwilling to use effective birth control during and for 3 months after treatment

What participation looks like

In the first phase of the trial, you would take the medication by mouth in 28-day cycles while researchers carefully monitor your dose and side effects to find the safest dose. In the second phase, you would continue taking the medication at the established dose in ongoing 28-day cycles. Some participants may also receive a single dose of the medication before having a biopsy or brain surgery. You would have regular clinic visits for blood work, scans, and check-ups to see how well the treatment is working and to track any side effects.

Testing a new medication for recurrent brain tumors with specific genetic mutations

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)